CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体（CAR）-T 细胞治疗相关不良事件全谱
英文原题：Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
查看英文原题
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已获美国食品药品监督管理局批准，用于治疗复发/难治性血液系统恶性肿瘤。然而，CAR-T 相关不良反应复杂，诊断和治疗均可能具有挑战性。本文综述主要不良事件，包括细胞因子释放综合征（CRS）、免疫效应细胞相关神经毒性综合征（ICANS）及CAR-T 相关噬血细胞性淋巴组织细胞增多症（carHLH），并讨论其病理生理机制、症状、分级与诊断系统以及管理方法。展望部分还概述了目前正在探索的限制CAR-T 毒性的措施和细胞改造策略。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies.
However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR T-cell associated HLH (carHLH), and discuss their pathophysiology, symptoms, grading, and diagnosis systems, as well as management. In a future outlook, we also provide an overview of measures and modifications to CAR-T cells that are currently being explored to limit toxicity.
论文信息
- 作者
- Yang C、Nguyen J、Yen Y
- 第一作者单位
- Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA, USA.United States
- 通讯作者单位
- College of Medical Technology, Taipei Medical University, Taipei City, Taiwan. yyen@tmu.edu.tw.Taiwan
- 文献类型
- 综述
- 期刊
- Journal of biomedical science2023 Oct 21
- 原文标识
- PubMed 37864230 · DOI 10.1186/s12929-023-00982-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →